(Q40621073)

22 September 2017

title

Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains (English)

1 reference

22 September 2017

1 reference

8

Joseph Sodroski

1 reference

22 September 2017

5

Peter D Kwong

1 reference

22 September 2017

Shi-Hua Xiang

1

1 reference

22 September 2017

Liping Wang

2

1 reference

22 September 2017

Mariam Abreu

3

1 reference

22 September 2017

Chih-Chin Huang

4

1 reference

22 September 2017

Eric Rosenberg

6

1 reference

22 September 2017

James E. Robinson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14592765

27 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

22 September 2017

10 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14592765

27 March 2024

number of pages

11

1 reference

full work available at URL

inferred from page(s)

https://digitalcommons.unl.edu/cgi/viewcontent.cgi?article=1216&context=virologypub

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14592765

https://api.elsevier.com/content/article/PII:S004268220300521X?httpAccept=text/xml

27 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0042-6822(03)00521-X

https://api.elsevier.com/content/article/PII:S004268220300521X?httpAccept=text/plain

27 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0042-6822(03)00521-X

27 March 2024

1 reference

22 September 2017

volume

315

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

124-134

1 reference

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

STI and beyond: the prospects of boosting anti-HIV immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Antibodies, viruses and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Identification of a major co-receptor for primary isolates of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Neutralizing antibodies against HIV -- back in the major leagues?

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Monoclonal antibodies against micro-organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

HIV-1 neutralizing antibodies: how full is the bottle?

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies).

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Neutralizing antibody responses to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

A role for carbohydrates in immune evasion in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Characterization of HIV-1-specific T-helper cells in acute and chronic infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Epitopes of the CD4 antigen and HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Neutralizing antiviral antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900521-X

7 January 2021

Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies

17

1 reference

https://api.crossref.org/works/10.1016/S0042-6822(03)00521-X

Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

27 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/S0042-6822(03)00521-X

An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection

27 March 2024

46

1 reference

https://api.crossref.org/works/10.1016/S0042-6822(03)00521-X

27 March 2024

Identifiers

1 reference

22 September 2017

1 reference